Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

被引:53
作者
Curtin, Nicola [1 ]
Banyai, Krisztian [2 ]
Thaventhiran, James [3 ]
Le Quesne, John [3 ,4 ,5 ]
Helyes, Zsuzsanna [6 ,7 ,8 ]
Bai, Peter [9 ,10 ,11 ]
机构
[1] Newcastle Univ, Ctr Canc, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
[2] Ctr Agr Res, Inst Vet Med Res, Budapest, Hungary
[3] Univ Cambridge, MRC Toxicol Unit, Leicester, Leics, England
[4] Univ Leicester, Leicester Canc Res Ctr, Leicester Royal Infirm, Leicester, Leics, England
[5] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Leicester, Leics, England
[6] Univ Pecs, Med Sch, Dept Pharmacol & Pharmacotherapy, Pecs, Hungary
[7] Univ Pecs, Ctr Neurosci, Pecs, Hungary
[8] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary
[9] Univ Debrecen, Dept Med Chem, Fac Med, Egyet Ter 1, H-4032 Debrecen, Hungary
[10] MTA DE Lendulet Lab Cellular Metab, Debrecen, Hungary
[11] Univ Debrecen, Res Ctr Mol Med, Fac Med, Debrecen, Hungary
基金
匈牙利科学研究基金会; 英国医学研究理事会;
关键词
ADP-RIBOSE POLYMERASE; ACUTE LUNG INJURY; CORONAVIRUS NUCLEOCAPSID PROTEIN; GRADE OVARIAN-CARCINOMA; IN-VITRO EXPOSURE; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; POTENT INHIBITOR; CYTOKINE STORM; DOUBLE-BLIND;
D O I
10.1111/bph.15137
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clinically approved PARP inhibitors (PARPi) have a mild adverse effect profile and are well tolerated as continuous daily oral therapy. We review the evidence that justifies the repurposing of PARPi to block the proliferation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and combat the life-threatening sequelae of coronavirus disease 2019 (COVID-19) by several mechanisms. PARPi can effectively decrease IL-6, IL-1 and TNF-alpha levels (key interleukins in SARS-CoV-2-induced cytokine storm) and can alleviate subsequent lung fibrosis, as demonstrated in murine experiments and clinical trials. PARPi can tune macrophages towards a tolerogenic phenotype. PARPi may also counteract SARS-CoV-2-induced and inflammation-induced cell death and support cell survival. PARPi is effective in animal models of acute respiratory distress syndrome (ARDS), asthma and ventilator-induced lung injury. PARPi may potentiate the effectiveness of tocilizumab, anakinra, sarilumab, adalimumab, canakinumab or siltuximab therapy. The evidence suggests that PARPi would benefit COVID-19 patients and trials should be undertaken.
引用
收藏
页码:3635 / 3645
页数:11
相关论文
共 105 条
[71]   Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 [J].
Oza, Amit M. ;
Tinker, Anna V. ;
Oaknin, Ana ;
Shapira-Frommer, Ronnie ;
McNeish, Lain A. ;
Swisher, Elizabeth M. ;
Ray-Coquard, Isabelle ;
Bell-McGuinn, Katherine ;
Coleman, Robert L. ;
O'Malley, David M. ;
Leary, Alexandra ;
Chen, Lee-may ;
Provencher, Diane ;
Ma, Ling ;
Brenton, James D. ;
Konecny, Gottfried E. ;
Castro, Cesar M. ;
Giordano, Heidi ;
Maloney, Lara ;
Goble, Sandra ;
Lin, Kevin K. ;
Sun, James ;
Raponi, Mitch ;
Rolfe, Lindsey ;
Kristeleit, Rebecca S. .
GYNECOLOGIC ONCOLOGY, 2017, 147 (02) :267-275
[72]   Investigation of Poly (ADP-Ribose) Polymerase-1 Genetic Variants as a Possible Risk for Allergic Rhinitis [J].
Ozaydin, Ahmet ;
Akbas, Fahri ;
Aksoy, Fadlullah ;
Yildirim, Yavuz Selim ;
Demirhan, Hasan ;
Karakurt, Funda ;
Koc, Arzuhan ;
Onaran, Ilhan ;
Sultuybek, Gonul Kanigur .
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2014, 18 (01) :57-61
[73]   Poly(ADP-ribose) polymerase-1 (PARP-1) controls lung cell proliferation and repair after hyperoxia-induced lung damage [J].
Pagano, Alessandra ;
Metrailler-Ruchonnet, Isabelle ;
Aurrand-Lions, Michel ;
Lucattelli, Monica ;
Donati, Yves ;
Argiroffo, Constance Barazzone .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2007, 293 (03) :L619-L629
[74]   Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases [J].
Pazzaglia, Simonetta ;
Pioli, Claudio .
CELLS, 2020, 9 (01)
[75]   Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial [J].
Pujade-Lauraine, Eric ;
Ledermann, Jonathan A. ;
Selle, Frederic ;
Gebski, Val ;
Penson, Richard T. ;
Oza, Amit M. ;
Korach, Jacob ;
Huzarski, Tomasz ;
Poveda, Andres ;
Pignata, Sandro ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Harter, Philipp ;
Fujiwara, Keiichi ;
Ray-Coquard, Isabelle ;
Banerjee, Susana ;
Liu, Joyce ;
Lowe, Elizabeth S. ;
Bloomfield, Ralph ;
Pautier, Patricia .
LANCET ONCOLOGY, 2017, 18 (09) :1274-1284
[76]   Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer [J].
Ramalingam, Suresh S. ;
Blais, Normand ;
Mazieres, Julien ;
Reck, Martin ;
Jones, C. Michael ;
Juhasz, Erzsebet ;
Urban, Laszlo ;
Orlov, Sergey ;
Barlesi, Fabrice ;
Kio, Ebenezer ;
Keiholz, Ulrich ;
Qin, Qin ;
Qian, Jiang ;
Nickner, Caroline ;
Dziubinski, Juliann ;
Xiong, Hao ;
Ansell, Peter ;
McKee, Mark ;
Giranda, Vincent ;
Gorbunova, Vera .
CLINICAL CANCER RESEARCH, 2017, 23 (08) :1937-1944
[77]   Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [J].
Robson, Mark ;
Im, Seock-Ah ;
Senkus, Elzbieta ;
Xu, Binghe ;
Domchek, Susan M. ;
Masuda, Norikazu ;
Delaloge, Suzette ;
Li, Wei ;
Tung, Nadine ;
Armstrong, Anne ;
Wu, Wenting ;
Goessl, Carsten ;
Runswick, Sarah ;
Conte, Pierfranco .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06) :523-533
[78]   PARP1 and Poly(ADP-ribosyl)ation Signaling during Autophagy in Response to Nutrient Deprivation [J].
Rodriguez-Vargas, Jose Manuel ;
Javier Oliver-Pozo, Francisco ;
Dantzer, Francoise .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
[79]   Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response [J].
Sahu, Bijayani ;
Narota, Arun ;
Naura, Amarjit S. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 877
[80]   Influence of PARP-1 Polymorphisms in Patients after Traumatic Brain Injury [J].
Sarnaik, Ajit A. ;
Conley, Yvette P. ;
Okonkwo, David O. ;
Barr, Taura L. ;
Fink, Ericka L. ;
Szabo, Csaba ;
Kochanek, Patrick M. ;
Clark, Robert S. B. .
JOURNAL OF NEUROTRAUMA, 2010, 27 (03) :465-471